Allianz SE Makes New $29.31 Million Investment in Eli Lilly and Company (NYSE:LLY)

Allianz SE acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 37,877 shares of the company’s stock, valued at approximately $29,310,000. Eli Lilly and Company makes up about 0.8% of Allianz SE’s portfolio, making the stock its 24th largest holding.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Principal Financial Group Inc. increased its position in shares of Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after purchasing an additional 60,306 shares during the last quarter. Fiduciary Trust Co grew its stake in shares of Eli Lilly and Company by 6.5% during the third quarter. Fiduciary Trust Co now owns 8,561 shares of the company’s stock worth $7,584,000 after purchasing an additional 522 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in Eli Lilly and Company by 0.9% in the third quarter. Hantz Financial Services Inc. now owns 17,961 shares of the company’s stock valued at $15,912,000 after buying an additional 155 shares during the last quarter. Carl P. Sherr & Co. LLC raised its stake in Eli Lilly and Company by 0.4% in the third quarter. Carl P. Sherr & Co. LLC now owns 5,526 shares of the company’s stock valued at $4,896,000 after buying an additional 24 shares in the last quarter. Finally, CWS Financial Advisors LLC lifted its holdings in Eli Lilly and Company by 7.3% during the 3rd quarter. CWS Financial Advisors LLC now owns 1,200 shares of the company’s stock worth $1,063,000 after buying an additional 82 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $820.30 on Friday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The business has a 50 day simple moving average of $844.31 and a 200-day simple moving average of $836.82. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The stock has a market capitalization of $777.78 billion, a PE ratio of 70.05, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company declared that its board has authorized a share buyback program on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. Truist Financial increased their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a report on Thursday, March 6th. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Finally, Bank of America reissued a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.